• Remplir nerve repair device used in 23 surgical procedures on injured Ukrainian soldiers
• Surgeons provided positive feedback on the device's clinical utility and suitability for major trauma applications
• Orthocell provided remote training to Ukrainian surgeons, demonstrating the accessibility of the device

Regenerative medicine company Orthocell Limited has announced that its Remplir nerve repair device has been used in 23 surgical procedures on injured soldiers in Ukraine. Following a humanitarian delivery of Remplir to Ukraine in April 2025, Orthocell has received confirmation that the device has been successfully utilized by Ukrainian surgeons in both primary and secondary nerve repair procedures. Surgeon feedback has been very positive, supporting the clinical utility of the device. This real-world use in a conflict setting highlights key attributes of Remplir, including its portability, ease of use, and suitability for major trauma applications in the defence forces. Importantly, Orthocell provided remote training to Ukrainian surgeons via video, supported by Australian Orthopedic Surgeon and Orthocell Key Opinion Leader Dr Alex O'Beirne, who delivered a comprehensive training module. The successful adoption of Remplir following remote instruction further demonstrates the practicality and accessibility of the device in challenging environments. Orthocell intends to continue engagement with Ukrainian surgeons to monitor patient outcomes and, where possible, collect clinical data. This information is expected to support ongoing and future discussions with defence organizations globally.

Orthocell has not provided any high-importance, price-sensitive forward-looking financial metrics or other company-specific metrics in the announcement.

Orthocell intends to continue engagement with Ukrainian surgeons to monitor patient outcomes and collect clinical data, which is expected to support ongoing and future discussions with defence organizations globally.